First Berlin Equity Research Reiterates BUY Rating for CEL-SCI Corporation, Sets Price Target at USD 60

Reuters09-01

<a href="https://laohu8.com/S/FTFI">First Berlin</a> Equity Research Reiterates BUY Rating for <a href="https://laohu8.com/S/CVM">CEL-SCI Corp</a>oration, Sets Price Target at USD 60

First Berlin Equity Research GmbH has issued a research update on CEL-SCI Corporation, maintaining a "BUY" recommendation with a revised target price of USD 60. Analyst Christian Orquera highlighted CEL-SCI's approach to a pivotal commercial inflection point in 2025, particularly noting the filing for Breakthrough Medicine Designation with the Saudi Food & Drug Authority for its lead immunotherapy, Multikine, targeting head and neck cancer. The collaboration with Dallah Pharma, a major Saudi pharmaceutical company, is expected to enhance Multikine's market potential in Saudi Arabia. Despite the price target reduction from USD 186 due to a reverse stock split and projected dilution, CEL-SCI is seen as a substantially de-risked player in the immuno-oncology field with several value catalysts anticipated in the coming year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: rc_23398), on September 01, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2564681488?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-01 19:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564681488","market":"us","top_or_hot":-1,"title":"First Berlin Equity Research Reiterates BUY Rating for CEL-SCI Corporation, Sets Price Target at USD 60","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FTFI\">First Berlin</a> Equity Research Reiterates BUY Rating for <a href=\"https://laohu8.com/S/CVM\">CEL-SCI Corp</a>oration, Sets Price Target at USD 60\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        First Berlin Equity Research GmbH has issued a research update on CEL-SCI Corporation, maintaining a \"BUY\" recommendation with a revised target price of USD 60. Analyst Christian Orquera highlighted CEL-SCI's approach to a pivotal commercial inflection point in 2025, particularly noting the filing for Breakthrough Medicine Designation with the Saudi Food &amp; Drug Authority for its lead immunotherapy, Multikine, targeting head and neck cancer. The collaboration with Dallah Pharma, a major Saudi pharmaceutical company, is expected to enhance Multikine's market potential in Saudi Arabia. Despite the price target reduction from USD 186 due to a reverse stock split and projected dilution, CEL-SCI is seen as a substantially de-risked player in the immuno-oncology field with several value catalysts anticipated in the coming year.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: rc_23398), on September 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>First Berlin Equity Research Reiterates BUY Rating for CEL-SCI Corporation, Sets Price Target at USD 60</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFirst Berlin Equity Research Reiterates BUY Rating for CEL-SCI Corporation, Sets Price Target at USD 60\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-01 19:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FTFI\">First Berlin</a> Equity Research Reiterates BUY Rating for <a href=\"https://laohu8.com/S/CVM\">CEL-SCI Corp</a>oration, Sets Price Target at USD 60\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        First Berlin Equity Research GmbH has issued a research update on CEL-SCI Corporation, maintaining a \"BUY\" recommendation with a revised target price of USD 60. Analyst Christian Orquera highlighted CEL-SCI's approach to a pivotal commercial inflection point in 2025, particularly noting the filing for Breakthrough Medicine Designation with the Saudi Food &amp; Drug Authority for its lead immunotherapy, Multikine, targeting head and neck cancer. The collaboration with Dallah Pharma, a major Saudi pharmaceutical company, is expected to enhance Multikine's market potential in Saudi Arabia. Despite the price target reduction from USD 186 due to a reverse stock split and projected dilution, CEL-SCI is seen as a substantially de-risked player in the immuno-oncology field with several value catalysts anticipated in the coming year.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: rc_23398), on September 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CVM","symbol_name":"CEL-SCI Corp","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250901:nNDL8kwbFr:1","article_id":"2564681488","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564681488","pubTimestamp":1756726703,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"First Berlin Equity Research GmbH has issued a research update on CEL-SCI Corporation, maintaining a \"BUY\" recommendation with a revised target price of USD 60. Analyst Christian Orquera highlighted CEL-SCI's approach to a pivotal commercial inflection point in 2025, particularly noting the filing for Breakthrough Medicine Designation with the Saudi Food & Drug Authority for its lead immunotherapy, Multikine, targeting head and neck cancer. The collaboration with Dallah Pharma, a major Saudi pharmaceutical company, is expected to enhance Multikine's market potential in Saudi Arabia. Despite the price target reduction from USD 186 due to a reverse stock split and projected dilution, CEL-SCI is seen as a substantially de-risked player in the immuno-oncology field with several value catalysts anticipated in the coming year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information,","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"CVM":"CEL-SCI Corp"},"translate_title":"First Berlin Equity Research重申CEL-SCI Corporation的买入评级，将目标价定为60美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVM":0.9},"content_text":"First Berlin Equity Research Reiterates BUY Rating for CEL-SCI Corporation, Sets Price Target at USD 60\n    \n\n        First Berlin Equity Research GmbH has issued a research update on CEL-SCI Corporation, maintaining a \"BUY\" recommendation with a revised target price of USD 60. Analyst Christian Orquera highlighted CEL-SCI's approach to a pivotal commercial inflection point in 2025, particularly noting the filing for Breakthrough Medicine Designation with the Saudi Food & Drug Authority for its lead immunotherapy, Multikine, targeting head and neck cancer. The collaboration with Dallah Pharma, a major Saudi pharmaceutical company, is expected to enhance Multikine's market potential in Saudi Arabia. Despite the price target reduction from USD 186 due to a reverse stock split and projected dilution, CEL-SCI is seen as a substantially de-risked player in the immuno-oncology field with several value catalysts anticipated in the coming year.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: rc_23398), on September 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2564681488","isCrawlerRequest":true}